Dyadic Q1 2024 net loss $2.01M ($0.07/share), revenue $335K; cash $12.1M; Phase 1 COVID booster successful

DYADIC INTERNATIONAL INC

Net loss $2.01M ($0.07 per share) vs $0.956M ($0.03) in Q1 2023; revenue down to $335K from $934K.
Cash and securities $12.1M as of Mar 31, 2024, up from $7.3M at Dec 31, 2023.
Phase 1 trial of DYAI-100 COVID booster completed; met safety and antibody response endpoints.
Issued $6.0M convertible notes (8%, due 2027) on Mar 8, 2024; appointed Patrick Lucy Chairman and Joe Hazelton COO.
Multiple collaborations with top pharma, ViroVax for H5N1 vaccine, and other partnerships.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DYADIC INTERNATIONAL INC reported financial results for first quarter of 2024.

Period: first quarter of 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Dyadic International, Inc. (“Dyadic”) issued a press release announcing its results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

DYADIC INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001437749-24-016675

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.